A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to help answer the following research question(s):
- To test if taking LY2599506 for 12 weeks controls blood sugar better than taking
glyburide for 12 weeks.
- To evaluate the safety of LY2599506 in participants with diabetes.
- To determine if LY2599506 has the ability to control blood sugar in participants with
diabetes.
- To determine how much LY2599506 should be given to participants.
- To determine if LY2599506 has an effect on a participant's weight.
The study design consists of 4 study periods: a screening period, a 4-week dose adjustment
period, an 8-week treatment period, and a 4-week follow up period.